US stock · Healthcare sector · Biotechnology
Company Logo

Geron Corporation

GERNNASDAQ

3.23

USD
+0.01
(+0.31%)
Pre Market
-9.97P/E
-8Forward P/E
-0.45P/E to S&P500
1.451BMarket CAP
- -Div Yield
Upcoming Earnings
8 Mar-13 Mar
Shares Short
1/13/23
22.71M
Short % of Float
5.08%
Short % of Shares Outs.
5.06%
% Held by Insiders
0.18%
% Held by Institutions
58.24%
Beta
0.67
PEG Ratio
-1.71
52w. high/low
3.84/1.00
Avg. Daily Volume
8.43M
Return %
Stock
S&P 500
1 year
216.67
(8.58)
3 years
142.86
23.39
5 years
- -
- -
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.99
0.95
2.14
0.98
2.40
0.75
2.36
1.19
3.06
0.99
3.84
2.34
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
0.05
0.10
0.04
0.02
0.04
0.02
0.02
0.01
0.01
0.23
0.04
0.01
0.01
0.00
0.00
0.00
0.00
Earnings per share
(0.47)
(0.49)
(0.79)
(0.80)
(1.14)
(0.78)
(0.54)
(0.30)
(0.23)
0.00
(0.19)
(0.18)
(0.15)
(0.36)
(0.28)
(0.35)
(0.36)
FCF per share
(0.41)
(0.40)
(0.57)
(0.51)
(0.46)
(0.51)
(0.44)
(0.29)
0.06
(0.15)
(0.12)
(0.13)
(0.12)
(0.23)
(0.25)
(0.29)
(0.31)
Dividends per share
- -
- -
- -
- -
0.00
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.01
0.04
0.03
0.02
0.01
0.00
0.01
0.00
0.00
0.00
0.00
- -
0.00
0.00
0.00
0.00
0.00
Book Value per sh.
2.63
2.77
2.15
1.96
1.97
1.18
0.67
0.47
0.85
0.90
0.77
0.65
1.01
0.71
0.78
0.39
0.32
Comm.Shares outs.
66
74
78
88
98
125
127
128
154
158
159
159
177
190
271
328
368
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(21.4)
(4.0)
(5.8)
(4.4)
(10.0)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.9)
(0.2)
(0.2)
(0.1)
(0.5)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
3
8
3
2
4
2
3
1
1
36
6
1
1
0
0
1
2
Operating margin
(1,445.2)%
(824.4)%
(2,391.9)%
(4,069.2)%
(3,120.0)%
(3,942.4)%
(2,648.9)%
(3,036.5)%
(3,149.3)%
(1.5)%
(497.3)%
(2,746.9)%
(2,914.9)%
(15,762.0)%
(30,400.4)%
(8,183.7)%
(19,516.5)%
Depreciation (m)
2
2
2
2
2
2
1
0
0
0
0
0
0
1
1
1
1
Net profit (m)
(31)
(37)
(62)
(70)
(111)
(97)
(69)
(38)
(36)
0
(30)
(28)
(27)
(69)
(76)
(116)
(131)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net profit margin
(957.1)%
(481.5)%
(2,212.7)%
(4,066.3)%
(3,125.9)%
(3,972.6)%
(2,542.7)%
(2,991.3)%
(3,093.7)%
0.1%
(479.3)%
(2,621.2)%
(2,534.4)%
(14,901.7)%
(29,888.1)%
(8,335.4)%
(19,971.7)%
Working capital (m)
170
201
161
110
154
112
84
59
112
109
108
89
159
113
169
142
139
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
24
54
42
Equity (m)
174
206
168
173
193
147
86
60
131
142
122
104
178
135
211
126
108
ROIC
- -
- -
- -
- -
- -
- -
(80.1)%
(64.1)%
(27.2)%
0.1%
(24.1)%
(26.8)%
(15.2)%
(49.9)%
(31.2)%
(62.3)%
(83.6)%
Return on capital
(14.1)%
(16.7)%
(35.1)%
(38.8)%
(47.6)%
(60.4)%
(68.8)%
(56.9)%
(20.6)%
0.1%
(22.6)%
(25.2)%
(14.6)%
(41.4)%
(27.7)%
(49.7)%
(53.9)%
Return on equity
(18.0)%
(17.8)%
(36.8)%
(40.7)%
(57.8)%
(66.1)%
(80.4)%
(64.2)%
(27.3)%
0.0%
(24.1)%
(26.9)%
(15.2)%
(50.7)%
(35.8)%
(91.8)%
(121.4)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.6%
- -
- -
- -
- -
- -
- -
- -
Capital Structure
7 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 124
Total assets
$ 233
Long-term debt
$ 42
Cash and equiv.
$ 61
Goodwill
$ - -
Retained earnings
$ (1,371)
Common stock
405
Enterprise Value
$ 1,432
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
139
196
184
Receivables
1
1
2
Inventory
- -
- -
- -
Other
1
(1)
23
Current assets
142
200
187
Acc. Payable
1
7
7
Debt due
0
1
1
Other
27
23
38
Current liabilities
28
31
46
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
450.59%
87.21%
352.75%
Cash flow
42.82%
51.77%
(36.51)%
Earnings
53.55%
53.59%
(7,139.27)%
Dividends
- -
- -
- -
Book value
(40.07)%
15.82%
14.60%
Insider Trading
Type
Shares
Date
Eastham Karin
Exempt
35,000
01/13/23
Eastham Karin
Exempt
35,000
01/13/23
Spiegel Robert J.
Award
2,970
12/30/22
Kapur Anil
Award
6,021
12/30/22
Spiegel Robert J.
Award
3,071
09/30/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
0
0
0
0
0
2021
0
0
0
1
1
2022
0
0
0
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.06)
(0.06)
(0.07)
(0.09)
(0.28)
2021
(0.08)
(0.09)
(0.08)
(0.10)
(0.35)
2022
(0.09)
(0.07)
(0.10)
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Dr. John Scarlett
Full-time employees:
98
City:
Foster City
Address:
919 EAST HILLSDALE BOULEVARD, SUITE 250
IPO:
Jul 31, 1996
Website:
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Recent News